Biomendex Receives FDA 510(k) Clearance for Adaptos® Fuse, enabling U.S. Commercial Launch of Its Bone Regeneration Platform
Tampere, Finland — 18-Feb, 2026 Biomendex today announced that Adaptos® Fuse Bone Graft has received U.S. Food and Drug Administration (FDA) 510(k) clearance as a bone graft substitute for filling bony voids or gaps that…
Read more »




